Atresmedia Sells Fever Labs for €227M, Distributes Extra €0.83 Dividend

Atresmedia: €227 Million in Cash and a Stock Price That Doesn't Reflect It

To some investors trinc the stock, Atresmedia is a cash-generating machine that the market prices as if it were on its deathbed; they argue it is not. The company closed the sale of its stake in Fever Labs for €227 million, recorded the return of litigation funds won against the Tax Agency, and yet, the stock price remained unresponsive. Only when it confirmed it would distribute this money as a dividend did the stock react with a 10% rise. Throughout 2025, the summary of the situation, according to this view, has not changed: solid business, healthy balance sheet, and a shareholder who isn't fully realizing the value within.

What Peine to the Fever Labs Money

Since March 2020, when the pandemic downturn hit the markets, the thesis of one of the investors trinc the stock was simple: hold on, collect the dividend, and wait. During this time, the company has distributed €2.2 per share, after an initial year with no payout. The performance, according to one of the most common perspectives in tracking the stock, has never lived up to the business's potential. The reason cited is always the same: a management team that prefers a cash cushion to the risk of growth.

The company, however, is no longer the same. While traditional TV advertising investment fell sharply, diversification continued. Clear Channel España was acquired, adding about €100 million to the perimeter, radio grew, and a media investment arm through equity stakes was bolstered, the value of which the stock market is still debating.

The €0.83 Extraordinary Dividend and Its Real Impact

The sale of Fever Labs was cashed in. Immediately after, the company announced an extraordinary dividend of €0.83 per share payable on December 16th, in addition to the €0.42 ordinary dividend for the year. In total, over one euro per share goes directly into the shareholder's pocket. The Lara family, owners of approximately half the capital, pocketed over €100 million.

With the remaining funds, the company would maintain, according to calculations from the forum, a net cash position of around €150 million after the distribution. The uncomfortable question looms: if you liquidate a gem, it's to do something with that money. Some suspect it will be used to buy production or platforms at inflated multiples; others believe it will simply swell the cash reserves aimlessly. Both interpretations are speculation, but the management's silence on their plans doesn't help dismiss either.

Atresmedia's Value If the Numbers Add Up

This is where the case gets interesting. The company had been earning €120 million net, which with an 80% payout policy and 225 million shares, yields €0.42 per share. Based on these foundations, scenarios range from prudent to optimistic. If profit returns to €120 million and the company trades at ten times earnings, the market capitalization would reach €1.2 billion plus the €200 million from Fever Labs: about €6.2 per share. If profit climbs to €150 million, the multiple rises, and with it, the valuation: €8.88. And in a euphoric scenario, with growth multiples, it reaches €12.

These are scenarios, not certainties. But the starting point is bothersome: with €350 million in cash and a market capitalization close to €1.1 billion, the business generating that cash would be valued, according to this view, at a bargain price.

The Telefónica Unknown and the Missing Narrative

There is a hypothesis proposed by a forum user that should be labeled as what it is: speculation. It suggests that Telefónica might spin off its television business and sell Atresmedia around 30% of a new joint venture. The company's cash reserves would allow for this. It would provide scale and proprietary content, although no one has confirmed that any discussion even exists.

The underlying problem, however, is not operational. It's about the narrative. Throughout the year, the company has been lowering its targets—promising to grow revenue to €1.06 billion with an EBITDA of 18% and ending up with a 15% target—without explaining the reason for each cut. An exercise in opacity that a portion of the shareholder base interprets directly as suspicion. According to this diagnosis, the stock isn't suffering from a lack of cash: it's suffering because no one is convincing the market that this cash will translate into growth.

If management presents a credible plan in the coming quarters—or executes a transformative acquisition that turns television into a cash cow and the rest into an engine—a re-rating should trinc. If they limit themselves, as they have so far, to distributing dividends and looking the other way, the stock will continue to trade below its balance sheet value. That gap isn't closed with patience. It's closed with decisions.